NCT07131189 - A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

August 10, 2025

Study Completion Date

August 10, 2026

Conditions

Locally Advanced/Metastatic Solid Tumors

Interventions

DRUG

FL115

FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).

Trial Locations (3)

ACTIVE_NOT_RECRUITING

Beijing Cancer Hospital, Beijing

ACTIVE_NOT_RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Suzhou Forlong Biotechnology Co.,Ltd,

INDUSTRY